Latest Medical Devices News

Nanosonics Limited reported a 9% revenue increase in the first half of FY26, driven by a growing installed base and recurring sales, while advancing the commercial rollout of its new CORIS endoscope reprocessing system.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

BTC Health reports a slight statutory loss in HY26 amid a 7% revenue dip, offset by strong growth in its cardio segment driven by key hospital contracts.

Clever Culture Systems posted a $1.32 million loss for the half year ending December 2025, reflecting a strategic shift and reduced government grants. Despite this, the company strengthened its cash position, repaid government debt, and grew its APAS Independence instrument footprint globally.

Tetratherix Limited reveals promising interim results for TetraDerm, its scar prevention product, showing minimal scarring in patients after skin lesion surgeries. The product’s unique approach could reshape wound closure in a $US2.1 billion market.

BTC Health’s investee, BTC Cardio, has landed exclusive Australian distribution rights for Jafron Biomedical’s hemoperfusion cartridges, aiming for a 2026 market debut pending regulatory approval.

ResMed Inc has updated the foreign exchange rate for its upcoming dividend payment to Australian CDI holders, impacting the Australian dollar amount payable per share. The dividend remains unfranked and subject to US withholding tax, with a reduced rate available under the US-Australia tax treaty.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.

Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.

Cochlear Limited reported a modest 1% rise in HY26 sales revenue to $1.176 billion, but underlying net profit fell 9% amid slower-than-expected contract renewals for its new Nucleus Nexa implant system. The company anticipates a stronger second half and maintains full-year guidance at the lower end of its forecast.